Currently, NeuroSense Therapeutics Ltd’s (NRSN) stock is trading at $1.13, marking a fall of -37.22% from last night’s close. At this price, the stock is -56.54% below its 52-week high of $2.60 and 88.81% above its 52-week low of $0.60.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, NRSN’s SMA-200 is $1.3179.
NRSN’s price to book ratio for the most recent quarter was 10.16, resulting in an 7.95 price to cash per share for the period.
How does NeuroSense Therapeutics Ltd (NRSN) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.
NeuroSense Therapeutics Ltd (NRSN): Earnings History
If we examine NeuroSense Therapeutics Ltd’s recent earnings history, in the last quarter ended on 12/31/2024, it posted adjusted earnings per share of -$0.06, slashing the consensus of -$0.15. In other words, it beat the consensus by $0.09, resulting in a 60.00% surprise. In the 3 months period before the previous quarter which was closed on 12/31/2024, the stock recorded adjusted earnings per share of -$0.06 in contrast with the Outlook of -$0.15. That was a difference of $0.09 and a surprise of 60.00%.
NeuroSense Therapeutics Ltd (NASDAQ: NRSN) Ownership Details
I will give a breakdown of the key shareholders in NeuroSense Therapeutics Ltd (NRSN). Recent figures show that the company’s insiders hold 30.98% of shares. A total of 11 institutional investors hold shares in the company, making 0.81% of its stock and 1.18% of its float.
Mar 31, 2025, it was reported that the Company’s largest institutional holder is Morgan Stanley holding total of 50.5 shares that make 0.21% of the company’s total number of shares and are currently priced at 56480.0.
The securities firm Meitav Investment House Ltd. holds 40.0 shares of NRSN, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.17%, and the holding percentage of shares is valued at 44735.0.
An overview of NeuroSense Therapeutics Ltd’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests NeuroSense Therapeutics Ltd (NRSN) traded 281,516 shares per day, with a moving average of $1.9519 and price change of -0.7400. With the moving average of $1.9470 and a price change of -0.4600, about 342,862 shares changed hands on average over the past 50 days. Finally, NRSN’s 100-day average volume is 259,294 shares, alongside a moving average of $1.5079 and a price change of +0.0877.
